Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 8, 2001, Pages 741-752

  Hagell, Peter ^a   Brundin, Patrik ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Autopsy; Dopamine; Neural transplantation; Parkinson disease; Positron emission tomography

Indexed keywords

FLUORINE 18;

AUTOPSY; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL ARTICLE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG UPTAKE; EMBRYONAL TISSUE; GRAFT SURVIVAL; HUMAN; MESENCEPHALON; PARKINSON DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REINNERVATION; REVIEW; TREATMENT OUTCOME;

EID: 0034921374     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.8.741     Document Type: Review

References (62)

1. Clinical observations after neural transplantation in Parkinson's disease
2. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach
3. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft
4. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease
5. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
6. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
7. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations
8. Transplantation of embryonic porcine mesencephalic tissue in patients with PD
9. Neural stem cells: From cell biology to cell replacement
10. 18F] fluorodopa uptake in five grafted parkinsonian patients
11. 18F] dopa-PET and clinical study of the rate of progression in Parkinson's disease
12. Functional effects of striatal dysfunction in Parkinson's disease
13. 18F] fluorodopa studies correlate with dopamine cell counts and levels
14. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease
15. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease
16. Caspase inhibition reduces apoptosis and increases survival of nigral transplants
17. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum
18. Lazaroids improve the survival of grafted rat embryonic dopamine neurons
19. Studies on neuromelanin. II Melanin in the brainstems of infants and children
20. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease
21. Dopamine and cholecystokinin immunoreactive neurons in mesencephalic grafts reinnervating the neostriatum: Evidence for selective growth regulation
22. Bilateral intrastriatal grafts of fetal mesencephalic neurons in Parkinson's disease: Long-term results in 9 patients
23. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
24. Fetal neural graft survival
25. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease
26. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease
27. Survival of TH-positive cells and graft-induced host dopaminergic sprouting in patients with Parkinson's disease after intrastriatal grafting of fetal ventral mesencephalon
28. Survival of TH-positive and neuromelanin-containing cells in patients with Parkinson's disease after inrastriatal grafting of fetal ventral mesencephalon
29. Neuropathology of dopaminergic transplants in patients with Parkinson's disease
30. Human fetal dopamine cells survive and develop processes after implantation into humans with Parkinson's disease
31. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
32. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies
33. Fetal grafting for Parkinson's disease: Expression of immune markers in two patients with functional fetal nigral grafts
34. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease
35. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts
36. Bilateral fetal grafts for Parkinson's disease: 22 Months' results
37. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease
38. Neural transplantation
39. Neural tissue xenotransplantation: What is needed prior to clinical trials in Parkinson's disease?
40. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease
41. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration
42. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method
43. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat
44. Transplantation of fetal tissue
45. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions
46. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease
47. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)
48. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease
49. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: An argument for neurotrophic supplementation
50. Neural transplantation in the ventral striatum
51. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications
52. Fetal nigral transplantation as a therapy for Parkinson's disease
53. Dopamine neurons grafted unilaterally to the nucleus accumbens affect drug-induced circling and locomotion
54. Effect of prior dopamine denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts
55. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry
56. Intranigral transplant of GABA-rich striatal tissue induce behavioral recovery in the rat parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants
57. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts
58. Delayed recovery of movement-related cortical function in Parkinson's disease following striatal dopaminergic grafts
59. Improving the survival of grafted dopaminergic neurons: A review over current approaches
60. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: Presurgical, and 1- and 2-year follow-up
61. Neural stem cells in the developing central nervous system: Implications for cell therapy through transplantation